Literature DB >> 16970641

Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease.

Paul Hollingworth1, Marian L Hamshere, Valentina Moskvina, Kimberley Dowzell, Pamela J Moore, Catherine Foy, Nicola Archer, Aoibhinn Lynch, Simon Lovestone, Carol Brayne, David C Rubinsztein, Brian Lawlor, Mike Gill, Michael J Owen, Julie Williams.   

Abstract

OBJECTIVES: To investigate behavioral components of Alzheimer's disease (AD) and to analyze behavioral components in relation to disease severity, apolipoprotein E genotype (APOE), sex, years of education, age at onset, and cognitive impairment.
DESIGN: Cross-sectional study.
SETTING: Data were collected from community-dwelling individuals and those residing in nursing homes. PARTICIPANTS: A total of 1,120 individuals meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for late-onset probable AD. MEASUREMENTS: Behavioral symptoms were assessed using the Neuropsychiatric Inventory. First-order polychoric correlations, controlling for disease severity, between the 12 symptom domain scores were estimated, and the resulting matrix underwent principal components analysis.
RESULTS: Four interpretable components were identified: behavioral dyscontrol (euphoria, disinhibition, aberrant motor behavior, and sleep and appetite disturbances), psychosis (delusions and hallucinations), mood (depression, anxiety, and apathy), and agitation (aggression and irritability). Scores on the four components were associated with severity of cognitive impairment. Higher behavioral dysfunction, agitation, and mood component scores were associated with lower age at onset. Behavioral dysfunction and mood component scores were associated with sex. None of the components were associated with age at assessment, years of education, or number of APOE epsilon4 alleles.
CONCLUSION: Four behavioral components were identified that were comparable with those observed previously. Future analysis of these components will strengthen understanding of the underlying pathology of behavioral symptoms and AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16970641     DOI: 10.1111/j.1532-5415.2006.00854.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  35 in total

1.  Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.

Authors:  Corinne E Fischer; Winnie Qian; Tom A Schweizer; Colleen P Millikin; Zahinoor Ismail; Eric E Smith; Lisa M Lix; Paul Shelton; David G Munoz
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 2.  Pharmacogenomics and therapeutic prospects in dementia.

Authors:  Ramón Cacabelos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

3.  Coping Strategies Utilized by Middle-Aged and Older Latino Caregivers of Loved Ones with Alzheimer's Disease and Related Dementia.

Authors:  Guilherme M Balbim; Isabela G Marques; Claudia Cortez; Melissa Magallanes; Judith Rocha; David X Marquez
Journal:  J Cross Cult Gerontol       Date:  2019-12

4.  A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.

Authors:  Zahinoor Ismail; Chetachi A Emeremni; Patricia R Houck; Sati Mazumdar; Jules Rosen; Tarek K Rajji; Bruce G Pollock; Benoit H Mulsant
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-02       Impact factor: 4.105

Review 5.  Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?

Authors:  Damien Gallagher; Nathan Herrmann
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 6.  Effective pain management in patients with dementia: benefits beyond pain?

Authors:  Elisabeth Flo; Christine Gulla; Bettina S Husebo
Journal:  Drugs Aging       Date:  2014-12       Impact factor: 3.923

7.  Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset.

Authors:  Josephine Barnes; Bradford C Dickerson; Chris Frost; Lize C Jiskoot; David Wolk; Wiesje M van der Flier
Journal:  Alzheimers Dement       Date:  2015-04-24       Impact factor: 21.566

8.  gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease.

Authors:  Lutgarde Serneels; Jérôme Van Biervliet; Katleen Craessaerts; Tim Dejaegere; Katrien Horré; Tine Van Houtvin; Hermann Esselmann; Sabine Paul; Martin K Schäfer; Oksana Berezovska; Bradley T Hyman; Ben Sprangers; Raf Sciot; Lieve Moons; Mathias Jucker; Zhixiang Yang; Patrick C May; Eric Karran; Jens Wiltfang; Rudi D'Hooge; Bart De Strooper
Journal:  Science       Date:  2009-03-19       Impact factor: 47.728

Review 9.  Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

Authors:  Ramón Cacabelos
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

10.  More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk.

Authors:  Samantha L Rosenthal; Mikhil N Bamne; Xingbin Wang; Sarah Berman; Beth E Snitz; William E Klunk; Robert A Sweet; F Yesim Demirci; Oscar L Lopez; M Ilyas Kamboh
Journal:  Neurobiol Aging       Date:  2015-04-25       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.